A BILL 
To amend the Public Health Service Act to establish an 
Office of Drug Manufacturing. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Affordable Drug Man-
4
ufacturing Act of 2019’’. 
5
SEC. 2. PUBLIC MANUFACTURING OF PHARMACEUTICALS. 
6
Part A of title III of the Public Health Service Act 
7
(42 U.S.C. 241 et seq.) is amended by adding at the end 
8
the following: 
9
20:16 Jan 06, 2020
H5501
2 
•HR 5501 IH
‘‘SEC. 310B. MANUFACTURING OF DRUGS. 
1
‘‘(a) ESTABLISHMENT OF OFFICE OF DRUG MANU-
2
FACTURING.— 
3
‘‘(1) IN GENERAL.—There is established within 
4
the Department of Health and Human Services an 
5
office to be known as the Office of Drug Manufac-
6
turing (referred to in this section as the ‘Office’). 
7
‘‘(2) PURPOSE.—The purpose of the Office is— 
8
‘‘(A) to increase competition, lower prices, 
9
and address shortages in the market for pre-
10
scription drugs, including insulin, naloxone, and 
11
antibiotics; 
12
‘‘(B) to reduce the cost of prescription 
13
drugs to Federal and State health programs, 
14
taxpayers, and consumers; and 
15
‘‘(C) to increase patient access to afford-
16
able drugs. 
17
‘‘(3) PERSONNEL.— 
18
‘‘(A) DIRECTOR.— 
19
‘‘(i) IN GENERAL.—The Office shall 
20
be headed by a Director, who shall be ap-
21
pointed by the President, by and with the 
22
advice and consent of the Senate. 
23
‘‘(ii) COMPENSATION.—The Director 
24
shall be compensated at the rate prescribed 
25
for level III of the Executive Schedule. 
26
20:16 Jan 06, 2020
H5501
3 
•HR 5501 IH
‘‘(B) EMPLOYEES.—The Director of the 
1
Office, in consultation with the Secretary, may 
2
fix the number of, and appoint and direct, all 
3
employees of the Office. 
4
‘‘(C) BANNED INDIVIDUALS.— 
5
‘‘(i) DRUG COMPANY LOBBYISTS.—No 
6
former registered drug manufacturer lob-
7
byist— 
8
‘‘(I) may be appointed to the po-
9
sition of Director of the Office; or 
10
‘‘(II) may be employed by the Of-
11
fice during the 6-year period begin-
12
ning on the date on which the reg-
13
istered lobbyist terminates its reg-
14
istration in accordance with section 
15
4(d) of the Lobbying Disclosure Act 
16
of 1995 (2 U.S.C. 1603(d)) or the 
17
agent terminates its status, as appli-
18
cable. 
19
‘‘(ii) SENIOR
EXECUTIVES
OF
LAW- 
20
BREAKING COMPANIES.—No former senior 
21
executive of a covered entity (as defined in 
22
clause (iii))— 
23
‘‘(I) may be appointed to the po-
24
sition of Director of the Office; or 
25
20:16 Jan 06, 2020
H5501
4 
•HR 5501 IH
‘‘(II) may be employed by the Of-
1
fice during the 6-year period begin-
2
ning on the later of— 
3
‘‘(aa) the date of the settle-
4
ment; and 
5
‘‘(bb) the date on which the 
6
enforcement 
action 
has 
con-
7
cluded. 
8
‘‘(iii) COVERED
ENTITY.—The term 
9
‘covered entity’ means any entity that is— 
10
‘‘(I) a drug manufacturer; and 
11
‘‘(II)(aa) operating under Fed-
12
eral settlement, including a Federal 
13
consent decree; or 
14
‘‘(bb) the subject of an enforce-
15
ment action in a court of the United 
16
States or by an agency. 
17
‘‘(4) DUTIES.— 
18
‘‘(A) IN GENERAL.—The Office shall— 
19
‘‘(i) prepare and submit applications 
20
for approval to the Food and Drug Admin-
21
istration, or enter into contracts for such 
22
submission, for the manufacture of appli-
23
cable drugs when authorized under this 
24
section; 
25
20:16 Jan 06, 2020
H5501
5 
•HR 5501 IH
‘‘(ii) acquire rights to manufacture 
1
applicable drugs as authorized under this 
2
section; 
3
‘‘(iii) manufacture, or enter into con-
4
tracts with entities to manufacture, appli-
5
cable drugs as authorized under this sec-
6
tion; 
7
‘‘(iv) determine a fair price for each 
8
applicable drugs, in accordance with sub-
9
paragraph (B); 
10
‘‘(v) 
sell 
manufactured 
applicable 
11
drugs at a fair price as authorized under 
12
this section; and 
13
‘‘(vi) manufacture, or enter into con-
14
tracts with entities to manufacture, active 
15
pharmaceutical ingredients for use by the 
16
Office or for sale to other entities. 
17
‘‘(B) FAIR PRICE.—In determining a fair 
18
price for an applicable drug under subpara-
19
graph (A)(iv) the Office shall consider— 
20
‘‘(i) the impact of price on patient ac-
21
cess to the applicable drug; 
22
‘‘(ii) the cost of the applicable drug to 
23
Federal or State health care programs; 
24
20:16 Jan 06, 2020
H5501
6 
•HR 5501 IH
‘‘(iii) the cost to the Federal Govern-
1
ment of manufacturing the applicable 
2
drug; 
3
‘‘(iv) the administrative costs of oper-
4
ating the Office; 
5
‘‘(v) the cost to acquire or manufac-
6
ture applicable drugs under this section; 
7
and 
8
‘‘(vi) the impact of price on market 
9
competition for the applicable drug. 
10
‘‘(C) ACQUIRING RIGHT TO MANUFACTURE 
11
AND
MARKET.—The Office may acquire the 
12
rights to manufacture and market applicable 
13
drugs as authorized under this section. 
14
‘‘(D) ACTIVE PHARMACEUTICAL INGREDI-
15
ENTS.— 
16
‘‘(i) IN GENERAL.—The Office shall 
17
manufacture, or enter into contracts with 
18
entities to manufacture, an active pharma-
19
ceutical ingredient if— 
20
‘‘(I) the Office determines that 
21
such ingredient is not readily available 
22
from existing suppliers; 
23
‘‘(II) the manufacture of such in-
24
gredient would improve the ability of 
25
20:16 Jan 06, 2020
H5501
7 
•HR 5501 IH
other entities to enter the market for 
1
the manufacture of generic drugs or 
2
otherwise expand the manufacture of 
3
generic drugs; or 
4
‘‘(III) the manufacture of such 
5
ingredient is necessary for the Office 
6
to carry out its duties under this sec-
7
tion. 
8
‘‘(ii) 
PRICE
DETERMINATIONS.—In 
9
determining what price at which to sell an 
10
active pharmaceutical ingredient under 
11
clause (i), the Office shall consider the cost 
12
to manufacture the ingredient, the admin-
13
istrative costs of the Office with respect to 
14
the ingredient, and the impact of such 
15
price on market competition for the ingre-
16
dient. 
17
‘‘(5) REPORTS
TO
CONGRESS.—The Director 
18
shall prepare and submit to the President, the Com-
19
mittee on Health, Education, Labor, and Pensions 
20
of the Senate, and the Committee on Energy and 
21
Commerce of the House of Representatives, an an-
22
nual report that includes— 
23
20:16 Jan 06, 2020
H5501
8 
•HR 5501 IH
‘‘(A) an assessment of the major problems 
1
faced by patients in accessing affordable generic 
2
medications; 
3
‘‘(B) a description of the status of all 
4
medications for which manufacturing has been 
5
authorized under this section, including medica-
6
tions being manufactured, medications for 
7
which the Office has submitted an application 
8
to the Food and Drug Administration but has 
9
not yet received approval, and medications for 
10
which the Office has received approval from the 
11
Food and Drug Administration but are not 
12
being manufactured; 
13
‘‘(C) in the case of antibiotics manufac-
14
tured under this section, an assessment from 
15
the Centers for Disease Control and Prevention 
16
and the Food and Drug Administration on the 
17
impact of the manufacturing of antibiotics on 
18
antimicrobial resistance; and 
19
‘‘(D) an analysis of how the public manu-
20
facture of drugs meeting the conditions de-
21
scribed in paragraph (6) would impact, or has 
22
already impacted, competition, access to such 
23
drugs, the costs of such drugs, the costs of pre-
24
20:16 Jan 06, 2020
H5501
9 
•HR 5501 IH
scription drugs to Federal and State health pro-
1
grams, and public health. 
2
‘‘(6) PRIORITY
MANUFACTURING.—The Office 
3
shall prioritize the manufacturing of those applicable 
4
drugs that would have the greatest impact on— 
5
‘‘(A) lowering drug costs to patients; 
6
‘‘(B) increasing competition and address-
7
ing shortages in the prescription drug market; 
8
‘‘(C) improving public health; or 
9
‘‘(D) reducing the cost of prescription 
10
drugs to Federal and State health programs. 
11
‘‘(7) MANUFACTURING
LEVELS.—Not later 
12
than 1 year after the date of enactment of this sec-
13
tion, the Office shall manufacture, or enter into con-
14
tracts with entities for the manufacture of, not less 
15
than 15 applicable drugs. Not later than 3 years 
16
after such date of enactment, the Office shall manu-
17
facture, or enter into contracts with entities for the 
18
manufacture of, not less than 25 applicable drugs. 
19
‘‘(b) SUBMISSION OF APPLICATIONS.—For each ap-
20
plicable drug that the Office determines should be manu-
21
factured, as provided for under this section, the Secretary 
22
shall— 
23
‘‘(1) submit an application under section 505(j) 
24
or 515 of the Federal Food, Drug, and Cosmetic Act 
25
20:16 Jan 06, 2020
H5501
10 
•HR 5501 IH
or section 351(k) of the Public Health Service Act 
1
or submit a notification under section 510(k) of the 
2
Federal Food, Drug, and Cosmetic Act (or enter 
3
into a contract with another entity to submit such 
4
an application or notification); or 
5
‘‘(2) acquire from the holder of an application 
6
approved under subsection (c) or (j) of section 505 
7
or section 515 of the Federal Food, Drug, and Cos-
8
metic Act or section 351 of the Public Health Serv-
9
ice Act, or cleared under section 510(k) of the Fed-
10
eral Food, Drug, and Cosmetic Act, rights to manu-
11
facture such applicable drug. 
12
‘‘(c) USE.— 
13
‘‘(1) IN GENERAL.—The Secretary shall sell a 
14
drug produced under this section at a fair price to 
15
other entities. Amounts received from the sale of 
16
such drugs shall be used for the activities of the Of-
17
fice. 
18
‘‘(2) SALE OF APPROVED APPLICATION.— 
19
‘‘(A) IN
GENERAL.—For any applicable 
20
drug that the Office is manufacturing, the Sec-
21
retary shall, beginning 3 years after the date on 
22
which the Office first undertakes manufacturing 
23
of such drug and annually thereafter, make 
24
available for sale, to any person who commits to 
25
20:16 Jan 06, 2020
H5501
11 
•HR 5501 IH
manufacturing and marketing the applicable 
1
drug, the approved application for the drug. 
2
‘‘(B) FAILURE TO USE.—If a person pur-
3
chasing an approved application under subpara-
4
graph (A)— 
5
‘‘(i) fails to market the applicable 
6
drug within 6 months of the date of such 
7
purchase; or 
8
‘‘(ii) increases the average manufac-
9
turer price for the applicable drug above 
10
the fair price (increased by the consumer 
11
price index for all urban consumers (as 
12
published by the Bureau of Labor Statis-
13
tics) for that year); 
14
the Secretary shall revoke the purchaser’s ap-
15
proved application and resume production of 
16
the applicable drug. 
17
‘‘(d) INSULIN.—Not later than 1 year after the date 
18
of enactment of this section, the Secretary shall begin the 
19
public manufacturing of insulin within a delivery device 
20
that does not violate active patents, meeting the definition 
21
of applicable drug and in accordance with this section. 
22
‘‘(e) NALOXONE.—Not later than 1 year after the 
23
date of enactment of this section, the Secretary shall begin 
24
the public manufacturing of naloxone, including naloxone 
25
20:16 Jan 06, 2020
H5501
12 
•HR 5501 IH
indicated for community use, meeting the definition of ap-
1
plicable drug and in accordance with this section. 
2
‘‘(f) ANTIBIOTICS.—Not later than 1 year after the 
3
date of enactment of this section, and in consultation with 
4
the Centers for Disease Control and Prevention and the 
5
Food and Drug Administration to ensure the appropriate 
6
use of manufactured antibiotics, the Secretary shall begin 
7
the public manufacturing of no fewer than three discrete 
8
antibiotics meeting the definition of applicable drug in ac-
9
cordance with this section. 
10
‘‘(g) APPLICABLE DRUG.—In this section, the term 
11
‘applicable drug’ means a drug (as defined in section 201 
12
of the Federal Food, Drug, and Cosmetic Act), biological 
13
product (as defined in section 351 of the Public Health 
14
Service Act), or combination product (as described in sec-
15
tion 503(g) of the Federal Food, Drug, and Cosmetic Act) 
16
for which an approved application under section 505 or 
17
515 of the Federal Food, Drug, and Cosmetic Act or sec-
18
tion 351 of the Public Health Service Act, or clearance 
19
under section 510(k) of the Federal Food, Drug, and Cos-
20
metic Act, is in effect, and— 
21
‘‘(1)(A) for which, with respect to a drug in-
22
cluded in the list described in section 505(j)(7) of 
23
the Federal Food, Drug, and Cosmetic Act, each 
24
patent included with respect to such drug in such 
25
20:16 Jan 06, 2020
H5501
13 
•HR 5501 IH
list has expired, or each patent that claims a biologi-
1
cal product has expired; 
2
‘‘(B) any period of regulatory exclusivity grant-
3
ed under— 
4
‘‘(i) clause (ii), (iii), or (iv) of section 
5
505(c)(3)(E) of the Federal Food, Drug, and 
6
Cosmetic Act, section 505(j)(5)(B)(iv) of such 
7
Act, clause (ii), (iii), or (iv) of section 
8
505(j)(5)(F) of such Act, section 527 of such 
9
Act, and any extension of such a period granted 
10
under section 505A or 505E of such Act, has 
11
expired; or 
12
‘‘(ii) paragraph (6) or (7) of section 351(k) 
13
of the Public Health Service Act, and any ex-
14
tension of such a period granted under para-
15
graph (2) or (3) of section 351(m) of such Act, 
16
has expired; and 
17
‘‘(C)(i) that is not being marketed in the 
18
United States; or 
19
‘‘(ii) that is being marketed in the United 
20
States by fewer than 3 manufacturers, and that— 
21
‘‘(I) in the previous 5-year period, has ex-
22
perienced an increase in the wholesale acquisi-
23
tion cost by at least one of its manufacturers 
24
that is greater than the consumer price index 
25
20:16 Jan 06, 2020
H5501
14 
•HR 5501 IH
for all urban consumers (as published by the 
1
Bureau of Labor Statistics) for one of the years 
2
in that the same period; 
3
‘‘(II) is included in the drug shortage list 
4
under section 506E of the Federal Food, Drug, 
5
and Cosmetic Act; or 
6
‘‘(III)(aa) has an average wholesale acqui-
7
sition cost that the Secretary determines to be 
8
a barrier to patient access; and 
9
‘‘(bb) is listed by the World Health Orga-
10
nization as an essential medicine; or 
11
‘‘(2) for which there is in effect a license, or 
12
patent use is authorized, under— 
13
‘‘(A) section 1498 of title 28, United 
14
States Code; 
15
‘‘(B) section 202 of title 35, United States 
16
Code; 
17
‘‘(C) section 203 of title 35, United States 
18
Code (march-in rights); 
19
‘‘(D) section 209 of title 35, United States 
20
Code; or 
21
‘‘(E) any other licensing authority of the 
22
Federal Government. 
23
20:16 Jan 06, 2020
H5501
15 
•HR 5501 IH
‘‘(h) AUTHORIZATION OF APPROPRIATIONS.—There 
1
are authorized to be appropriated such sums as may be 
2
necessary to carry out this section.’’. 
3
Æ 
20:16 Jan 06, 2020
H5501
